Volume 41, Issue 2, Pages (February 2002)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

The PSA Era is not Over for Prostate Cancer
Volume 59, Issue 2, Pages (February 2011)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 45, Issue 3, Pages (March 2004)
Volume 53, Issue 5, Pages (May 2008)
Control of Prostate Cancer by Transrectal HIFU in 227 Patients
Volume 69, Issue 1, Pages (January 2016)
Volume 61, Issue 2, Pages (February 2012)
Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?
Prostate Cancer Epidemic in Sight?
Volume 52, Issue 4, Pages (October 2007)
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
High Dose Rate Brachytherapy of Localized Prostate Cancer
Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka 
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Prostate Cancer Detection: A View of the Future
Obesity and Prostate Cancer: A Role for Adipokines
Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening?  Bob Djavan  European.
Shaheen Alanee, Kasmintan Schrader, Kenneth Offit  European Urology 
Counselling the Prostate Cancer Patient
Prostate Cancer Epidemic in Sight?
The PSA Era is not Over for Prostate Cancer
Molecular Tumour Profiling for Detection of Biomarkers in Renal Cell Tumours  Kerstin Junker, Jimsgene Sanjmyatav, Joerg Mueller, Thomas Steiner, Heiko.
Human Papilloma Virus, Histopathological, and Molecular Subtyping in Penile Cancer: Relevance for Prognosis and Therapy  Kerstin Junker, Sebastian Hölters,
Volume 53, Issue 2, Pages (February 2008)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 53, Issue 6, Pages (June 2008)
Mark A. Rubin, Gabriele Girelli, Francesca Demichelis  European Urology 
Volume 66, Issue 2, Pages (August 2014)
Volume 63, Issue 3, Pages (March 2013)
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Tillmann Loch, Pat Fox Fulgham  European Urology 
Volume 50, Issue 5, Pages (November 2006)
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Volume 55, Issue 3, Pages (March 2009)
Prostate Specific Antigen Doubling Time as Auxiliary End Point in Hormone Refractory Prostatic Carcinoma  Hans-Peter Schmid, Rudolf Morant, Jürg Bernhard,
Volume 4, Issue 1, Pages 4-6 (July 2003)
Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy  Bertrand Tombal, Richard Berges  European Urology.
Volume 69, Issue 5, Pages (May 2016)
Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis
Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice  Claus Roehrborn  European Urology.
Neal Shore  European Urology Supplements 
Volume 66, Issue 6, Pages (December 2014)
The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
How and When to Take Prostate Biopsies
Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma  Fred Saad  European Urology.
New Trends in Managing the Prostate Cancer Patient
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature  Liliana Vartolomei, Shahrokh F. Shariat, Mihai.
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Volume 56, Issue 4, Pages (October 1999)
Improving Flexibility and Quality of Life for Your Patients: A Must?
Volume 54, Issue 1, Pages (July 2008)
Volume 17, Issue 2, Pages (February 1950)
Familial amyloidosis: Great progress for an orphan disease
Prognostic Factors in Non–Muscle-Invasive Bladder Tumors
Volume 53, Issue 6, Pages (June 2008)
Management of Prostate Cancer: Global Strategies
Volume 53, Issue 2, Pages (February 2008)
Treatment Options in Prostate Cancer Once Primary Therapy Fails
Manfred Wirth, Peter Iversen, David McLeod, William See 
Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer  Sten Holmäng  European Urology.
Volume 56, Issue 4, Pages (October 1999)
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Epidemiology and Demographics of Prostatitis
New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer  Noel W. Clarke  European Urology Supplements 
Does PSA Testing Influence the Natural History of Prostate Cancer?
Presentation transcript:

Volume 41, Issue 2, Pages 167-171 (February 2002) Gain in Chromosome 8q Correlates with Early Progression in Hormonal Treated Prostate Cancer  Thomas Steiner, Kerstin Junker, Frank Burkhardt, Andreas Braunsdorf, Volker Janitzky, Joerg Schubert  European Urology  Volume 41, Issue 2, Pages 167-171 (February 2002) DOI: 10.1016/S0302-2838(01)00030-6

Fig. 1 Chromosomal aberrations in primary prostate biopsies; data are shown dependent on clinical course of disease. European Urology 2002 41, 167-171DOI: (10.1016/S0302-2838(01)00030-6)

Fig. 2 CGH Profiles showing multiple gains and losses of chromosome parts in a tumor with progression (patient no. 2): profile at the middle line: no changes; shift to the right borderline: gain of chromosome or part of a chromosome; shift to the left borderline: loss of chromosome or part of a chromosome. European Urology 2002 41, 167-171DOI: (10.1016/S0302-2838(01)00030-6)